The different ones GI discontinuation rate: 5.6% of semaglutide (Wegovy) users stopped due to GI side effects, vs 2.7% of Tirzepatide (Mounjaro) users Diarrhoea: Common with Mounjaro because of its dual action Nausea and constipation: Seen more in Wegovy MHRA NAION warning (February 2026) : Both medications carry an updated warning about a very rare but serious eye condition (non-arteritic anterior ischaemic optic neuropathy)
Information on Rybelsus is also maintained on our drug pages
If that resonates with you, its totally valid
"A higher body weight causes increased pressure on your upper airways," Wojeck says
It works through several mechanisms: Appetite regulation : Semaglutide acts on receptors in the brain's appetite centres, particularly the hypothalamus, reducing hunger and increasing satiety after meals Delayed gastric emptying : It slows the rate at which food leaves the stomach, prolonging feelings of fullness (this effect may be most pronounced during dose escalation) Glucose-dependent insulin secretion : In the presence of elevated blood glucose, it stimulates pancreatic beta cells to release insulin Glucagon suppression : It reduces inappropriate glucagon secretion from pancreatic alpha cells, thereby limiting hepatic glucose production These combined effects result in significant weight lossaround 15% of body weight in people without diabetes and approximately 9-10% in people with type 2 diabetes, according to clinical trialsand improved glycaemic control in people with type 2 diabetes
